Arbekacin: Another novel agent for treating infections due to methicillin-resistant Staphylococcus aureus and multidrug-resistant Gram-negative pathogens

Clinical Pharmacology: Advances and Applications

Volumn 6, Issue , 2014, Pages 139-148

  Matsumoto, Tetsuya ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Habekacin; MRSA; Multidrug resistant Gram negative bacteria; Synergistic effect

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE INACTIVATING ENZYME; AZTREONAM; BACTERIAL ENZYME; CARBAPENEM DERIVATIVE; COLISTIN; GENTAMICIN; HABEKACIN; LINEZOLID; RIFAMPICIN; TEICOPLANIN; TOBRAMYCIN; TOXIC SHOCK SYNDROME TOXIN 1; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ADULT; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CHILD; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DISEASE MODEL; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; ESCHERICHIA COLI; EXPERIMENTAL MOUSE; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MORAXELLA CATARRHALIS; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; POST ANTIBIOTIC EFFECT; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; STAPHYLOCOCCUS EPIDERMIDIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TOXIN SYNTHESIS;

EID: 84907693436     PISSN: None     EISSN: 11791438     Source Type: Journal    
DOI: 10.2147/CPAA.S44377     Document Type: Review

References (67)

1. Kondo S. [Development of arbekacin and synthesis of new derivatives stable to enzymatic modifications by methicillin-resistant Staphylococcus aureus]. Jpn J Antibiot. 1994;47(6):561–574. Japanese.
2. Tanaka N, Matsunaga K, Hirata A, Matsuhisa Y, Nishimura T. Mechanism of action of Habekacin, a novel amino acid containing aminoglycoside antibiotic. Antimicrob Agents Chemother. 1983;24(5):797–802.
3. Watanabe A, Yanagihara K, Matsumoto T, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2009: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2012;18(5):609–620.
4. Yamaguchi K, Ishii Y, Iwata M, et al. Meropenem [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006]. Jpn J Antibiot. 2007;60(6):344–377. Japanese.
5. Nishino T, Sakurai M. In vitro activity of everninomicin (SCH 27899). In: Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; October 17–20, 1993; Louisiana, New Orleans. Abstract No 462.
6. Okamoto R, Iyobe S, Mitsuhashi S. HBK [Antibacterial activity of HBK]. Chemother. 1986;34:1–10. Japanese.
7. Kazuno Y, Tsuneta S, Tamra A, et al. Bactriological evaluation of a new aminoglycoside antibiotic, HBK. Chemother. 1986;34:61–71.
8. Matsuhashi Y, Yamamoto H. [The enzymatic mechanisms of resistant to aminoglycoside antibiotics in methicillin-cephem-resistant Staphylococcus aureus]. Jpn J Antibiot. 1988;41(5):523–529. Japanese.
9. Niki Y, Hanaki H, Yagisawa M, et al. Japanese Society of Chemotherapy. The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility. J Infect Chemother. 2008;14(4):279–290.
10. Niki Y, Hanaki H, Matsumoto T, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2007: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2009;15(3):156–167.
11. Niki Y, Hanaki H, Matsumoto T, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2011;17(4):510–523.
12. Takesue Y, Watanabe A, Hanaki H, et al. Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan. J Infect Chemother. 2012;18(6):816–826.
13. Mikuniya T, Kato Y, Muto-Kobayashi Y, et al. Prevalence of drug resistant gene and changes in susceptibility of methicillin-resistant Staphylococcus aureus strains isolated from 1990 to 2006 in Japan to antimicrobial agents. Jpn J Chemother. 2009;61(5):37–40.
14. Watanabe T, Ohashi K, Matsui K, Kubota T. Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicilin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1997;39(4):471–476.
15. Flandrois JP, Fardel G, Carret G. Early stages of in vitro killing curve of LY146032 and vancomycin for Staphylococcus aureus. Antimicrob Agents Chemother. 1988;32(4):454–457.
16. Asseray N, Jacqueline C, Le Mabecque V, et al. Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy. Antimicrob Agents Chemother. 2005;49(2):857–859.
17. Takahashi T, Matsumoto F, Miyazaki S. Comparison of in vitro antibacterial activity of arbekacin, vancomycin and teicoplanin against methicillin-resistant Staphylococcus aureus. Jpn J Chemother. 1999; 47(2):103–107.
18. Kurazono M, Yamada K, Hirai Y, Ida T, Inoue M. MRSA. [Epidemiological survey of drug resistance of methicillin–resistant Staphylococcus aureus isolated in Japan in 2000]. Jpn J Chemother. 2002;50(8):494–499. Japanese.
19. Miyata A, Araake M, Ogawa H, Hanaki H, Hiramatsu K. MRSA Toxic shock syndrome toxin-1(TSST-1). [Effect of Arbekacin of the production of toxic shock syndrome toxin 1 by methicillin-resistant Staphylococcus aureus]. Jpn J Antibiotics. 2001;54(7):372–381. Japanese.
20. Araoka H, Baba M, Tateda K, et al. In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan. Jpn J Infect Dis. 2012;65(1):84–87.
21. Kataoka H, Ida T, Ishii Y, et al. Analysis of the influence of drug resistance factors on the efficacy of combinations of antibiotics for multidrug-resistant Pseudomonas aeruginosa isolated from hospitals located in the suburbs of Kanto area, Japan. Journal of Global Antimicrobial Resistance. 2013;1(2):91–96.
22. Zapor MJ, Barber M, Summers A, et al. In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center. Antimicrob Agents Chemother. 2010;54(7):3015–3017.
23. Overview of Habekacin Injectable Solution (additional pediatric indication). In-house document of Meiji Seika Kaisha, Ltd.
24. Aikawa N, Kohno S, Kaku M, Watanabe A, Yamaguchi K, Tanigawara Y. An open clinical study of arbekacin 200 mg qd in patients infected with methicillin-resistant Staphylococcus aureus (MRSA) – A clinical pharmacology study. Jpn J Chemother. 2008;56(3):299–312.
25. Sunakawa K, Hori S. [Safety and pharmacokinetics of 400 and 600 mg arbekacin sulfate to healthy male volunteers]. Jpn J Antibiotics. 2013;66(2):97–109. Japanese.
26. Suzuki K, Tanikawa K, Matsuzaki T. Pharmacokinetics and dosing of arbekacin in preterm and term newborn infants. Pediatr Int. 2003;45(2):175–179.
27. Kinoshita D. [Evaluation of once a day of arbekacin administration to neonates as a new object of peak concentration]. Kansenshogaku Zasshi. 2010;84(6):727–733. Japanese.
28. Funatsu Y, Hasegawa N, Namkoong H, et al. Penetration of arbekacin sulfate to the lung tissue. Proceedings of the 52nd interscience conference on antimicrobial agents and chemotherapy; September 9–12, 2012; San Francisco. Abstract No 2068.
29. Carcas AJ, Garcia-Satue JL, Zapater P, Frias-Iniesta J. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther. 1999;65(3):245–250.
30. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob. Agents Chemother. 2004;48(4):1159–1167.
31. Koga K, Kusawake Y, Ito Y, Sugioka N, Shibata N, Takada K. Enhancing mechanism of Labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfate. Eur J Pharm Biopharm. 2006;64(1):82–91.
32. Blaser J, Rieder HL, Luthy R. Interface-area-to-volume ratio of interstitial fluid humans determined by pharmacokinetic analysis of netilmicin in small and large skin blisters. Antimicrob Agents Chemother. 1991;35(5):837–839.
33. Dee TH, Kozin F. Gentamicin and tobramycin penetration into synovial fluid. Antimicrob Agents Chemother. 1977;12(4):548–549.
34. Thys JP, Serruvs-Schoutens E, Rocmans P, Herchuelz A, Vanderlinden MP, Yourassowsky E. Amikacin concentration in uninfected post thoracotomy pleural fluid and in serum after intravenous and intrapleural injection. Chest. 1984;85(4):502–505.
35. Kozak AJ, Gerding DN, Peterson LR, Hall WH. Gentamicin intravenous infusion rate: effect on interstitial fluid concentration. Antimicrob Agents Chemother. 1977;12(5):606–608.
36. Chisholm GD, Waterworth PM, Calnan JS, Garrod LP. Concentration of antibacterial agents in interstitial tissue fluid. Br Med J. 1973;1(5853): 569–573.
37. Lorentzen H, Kallehave F, Kolmos HJ, Knigge U, Bulow J, Gottrup F. Gentamicin concentrations in human subcutaneous tissue. Antimicrob Agents Chemoter. 1996;40(8):1785–1789.
38. Rosin E, Ebert S, Uphoff TS, Evans MH, Schultz-Darken NJ. Penetration of antibiotics into the surgical wound in a canine model. Antimicrob Agents Chemoter.1989;33(5):700–704.
39. Hayashi M, Ooi K, Yamada, et al. [Arbekacin sulfate concentration in peripheral lymph and in serum after intravenous injection: report of four cases]. Jpn J Antibiot. 2012;65(3):207–215. Japanese.
40. Okada K, Kimura T, Mikamo H, et al. Clinical practice guidelines for therapeutic drug monitoring of arbekacin: A consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Infect Chemother. 2014;20(1):1–5.
41. Shimizu A, Maebashi K, Niida M, et al. S03044. Pharmacokinetic-pharmacodynamic (PK-PD) study of arbekacin using mouse MRSA thigh infection model. In-house document of Meiji Seika Kaisha, Ltd; 2003.
42. Mattie H, Craig WA, Pechere JC. Determination of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989;24(3):281–293.
43. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1): 1–12.
44. Sato R, Tanigawara Y, Kaku M, Aikawa N, Shimizu K. Pharmacokinetic- pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(11):3763–3769.
45. Negita K, Yamashita M, Kubota T, et al. Study on therapeutic drug monitoring of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus and its efficacy. Jpn J Pharm Health Care Sci. 2001;27(2):123–131.
46. Nambara M, Ikeue H, Kawasaki E, Tomioka S, Shimokawa F, Tanabe K. Effectiveness and adverse reactions between once daily and every other day administration of arbekacin sulfate. Jpn J Ther Drug Monit. 2003;20(3):241–248.
47. Kobayashi M, Saikyo A, Soma K, Yago K, Sunakawa K. Pharmacokinetic and pharmacodynamics (PK-PD) analysis to determine the optimal method of arbekacin administration. Jpn J Chemother. 2006;54(1):18–24.
48. Tanikaze N, Komatsu M, Shimakawa K, Yamamoto I. [Study of clinical significance of PK/PD (pharmacokinetics/pharmacodynamics) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection]. Jpn J Chemother. 2004;52(9):469–473. Japanese.
49. Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, Lee CS. The usefulness of arbekacin compared to vancomycin. Eur J Clin Microbiol Infect Dis. 2012;31(7):1663–1666.
50. Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, Lee CS. The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue mrsa infection: preliminary study. Infect Chemother. 2013;45(1):62–68.
51. Matsumoto T, Hanaki H, Kimura T, et al. Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study. J Infect Chemother. 2013;19(1):128–137.
52. Kawano H, Tanigawara Y. Postmarketing surveillance review of arbekacin sulfate in patients with therapeutic drug monitoring. Jpn J Ther Drug Monit. 2010;27(2):55–71.
53. Yamamoto Y, Izumikawa K, Hashiguchi K, et al. The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection. J Infect Chemother. 2012;18(2):241–246.
54. Kimura T, Sunakawa K, Totsuka K, et al. Dose finding study on arbekacin sulfate for appropriate peak levels. Jpn J Chemother. 2011;59(6): 597–604.
55. Araoka H, Baba M, Takagi S, et al. Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a ‘break-point checkerboard plate’. Scand J Infect Dis. 2010;42(3):231–233.
56. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003–1012.
57. Swan SK. Aminoglycoside nephrotoxicity. Semin Nephrol. 1997;17(1): 27–33.
58. Giuliano RA, Verpooten GA, Verbist L, Wedeen RP, De Broe ME. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther. 1986;236(2):470–475.
59. Rougier F, Claude D, Maurin M, et al. Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother. 2003;47(3):1010–1016.
60. Chanbers HE. Chemotherapy of microbial diseases antimicrobial agents: the aminoglycosides. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th edition. New York: McGraw-Hill; 2001:1219–1238.
61. Huy PTB, Mannel C, Menlemans A. Kinetics of aminoglycoside antibiotics in perilymph in animals. In: Lerner SA, Martz GJ, Hawkins JE, editors. Aminoglycoside Ototoxicity. Little, Brown and Company; 1981; 81–97.
62. Tulkens PM, Clerckx-Braun F, Donnez J, et al. Safety and efficacy of aminoglycosides once-a-day: experimental data and randomized, controlled evaluation in patients suffering from pelvic inflammatory disease. J Drug Dev. 1988;1(Suppl 3):71–82.
63. Totsuka K, Shimizu K, Mitomi N, Niizato T, Araake M. Arbekacin. [Evaluation of once-daily administration of arbekacin]. Jpn J Antibiotics. 1994;47(6): 676–692. Japanese.
64. Bates DE. Aminoglycoside ototoxicity. Drugs Today (Barc). 2003; 39(4):277–285.
65. Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy – Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet. 1999;36(2):89–98.
66. Yamasoba T. Inner ear disorders and mitochondrial DNA mutation. Practica Oto-Rhino-Laryngologica. 2011;104(8):533–540.
67. Hamasaki K, Rando RR. Specific binding of aminoglycosides to a human rRNA construct based on a DNA polymorphism which causes aminoglycoside-induced deafness. Biochemistry. 1997;36(40):12323–12328.